Patterns of practice in the radiation therapy management of rectal cancer: Survey of the Interregional Group Piedmont, Valle d'Aosta and Liguria of the "associazione Italiana di Radioterapia Oncologica (AIRO)"

Milena Di Genesio Pagliuca, Lucia Turri, Fernando Munoz, Antonella Melano, Almalina Bacigalupo, Paola Franzone, Piera Sciacero, Vassiliki Tseroni, Maria Laura Vitali, Elena Delmastro, Tindaro Scolaro, Corrado Marziano, Marco Orsatti, Maria Tessa, Annalisa Rossi, Andrea Ballarè, Gregorio Moro, Rachele Grasso, Marco Krengli

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aims and background. To report the survey about the main aspects on the use of radiotherapy for the treatment of rectal cancer in Piedmont and Liguria. Methods and study design. Sixteen centers (11 from Piedmont and 5 from Liguria) received and answered by email a questionnaire data base about clinical and technical aspects of the treatment of rectal cancer. All data were incorporated in a single data base and analyzed. Results. Data regarding 593 patients who received radiotherapy for rectal cancer during the year 2009 were collected and analyzed. Staging consisted in colonoscopy, thoracic and abdominal CT, pelvic MRI and endoscopic ultrasound. PET/CT was employed to complete staging and in the treatment planning in 12/16 centers (75%). Neoadjuvant radiotherapy was employed more frequently than adjuvant radiotherapy (50% vs 36.4%), using typically a total dose of 45 Gy with 1.8 Gy/fraction. Concurrent chemoradiation with 5-fluorouracil or capecitabine was mainly employed in neoadjuvant and adjuvant settings, whereas oxaliplatin alone or in combination with 5-FU or capecitabine and leucovorin was commonly employed as the adjuvant agent. The median interval from neoadjuvant treatment to surgery was 7 weeks after longcourse radiotherapy and 8 days after short-course radiotherapy. The pelvic total dose of 45 Gy in the adjuvant setting was the same in all the centers. Doses higher than 45 Gy were employed with a radical intent or in case of positive surgical margins. Hypofractionated regimens (2.5, 3 Gy to a total dose of 35-30 Gy) were used in the palliative setting. No relevant differences were observed in target volume definition and patient setup. Twenty-six patients (4.4%) developed grade 3 acute toxicity. Follow-up was scheduled in a similar way in all the centers. Conclusions. No relevant differences were found among the centers involved in the survey. The approach can help clinicians to address important clinical questions and to improve consistency and homogeneity of treatments.

Original languageEnglish
Pages (from-to)61-67
Number of pages7
JournalTumori
Volume99
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Rectal Neoplasms
Radiotherapy
oxaliplatin
Fluorouracil
Databases
Adjuvant Radiotherapy
Neoadjuvant Therapy
Leucovorin
Colonoscopy
Therapeutics
Thorax
Surveys and Questionnaires
Capecitabine

Keywords

  • Management
  • Rectal cancer
  • Survey

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Patterns of practice in the radiation therapy management of rectal cancer : Survey of the Interregional Group Piedmont, Valle d'Aosta and Liguria of the "associazione Italiana di Radioterapia Oncologica (AIRO)". / Di Genesio Pagliuca, Milena; Turri, Lucia; Munoz, Fernando; Melano, Antonella; Bacigalupo, Almalina; Franzone, Paola; Sciacero, Piera; Tseroni, Vassiliki; Vitali, Maria Laura; Delmastro, Elena; Scolaro, Tindaro; Marziano, Corrado; Orsatti, Marco; Tessa, Maria; Rossi, Annalisa; Ballarè, Andrea; Moro, Gregorio; Grasso, Rachele; Krengli, Marco.

In: Tumori, Vol. 99, No. 1, 01.2013, p. 61-67.

Research output: Contribution to journalArticle

Di Genesio Pagliuca, M, Turri, L, Munoz, F, Melano, A, Bacigalupo, A, Franzone, P, Sciacero, P, Tseroni, V, Vitali, ML, Delmastro, E, Scolaro, T, Marziano, C, Orsatti, M, Tessa, M, Rossi, A, Ballarè, A, Moro, G, Grasso, R & Krengli, M 2013, 'Patterns of practice in the radiation therapy management of rectal cancer: Survey of the Interregional Group Piedmont, Valle d'Aosta and Liguria of the "associazione Italiana di Radioterapia Oncologica (AIRO)"', Tumori, vol. 99, no. 1, pp. 61-67. https://doi.org/10.1700/1248.13790
Di Genesio Pagliuca, Milena ; Turri, Lucia ; Munoz, Fernando ; Melano, Antonella ; Bacigalupo, Almalina ; Franzone, Paola ; Sciacero, Piera ; Tseroni, Vassiliki ; Vitali, Maria Laura ; Delmastro, Elena ; Scolaro, Tindaro ; Marziano, Corrado ; Orsatti, Marco ; Tessa, Maria ; Rossi, Annalisa ; Ballarè, Andrea ; Moro, Gregorio ; Grasso, Rachele ; Krengli, Marco. / Patterns of practice in the radiation therapy management of rectal cancer : Survey of the Interregional Group Piedmont, Valle d'Aosta and Liguria of the "associazione Italiana di Radioterapia Oncologica (AIRO)". In: Tumori. 2013 ; Vol. 99, No. 1. pp. 61-67.
@article{70bb503a824c4c848c9bfe6c2eb21e27,
title = "Patterns of practice in the radiation therapy management of rectal cancer: Survey of the Interregional Group Piedmont, Valle d'Aosta and Liguria of the {"}associazione Italiana di Radioterapia Oncologica (AIRO){"}",
abstract = "Aims and background. To report the survey about the main aspects on the use of radiotherapy for the treatment of rectal cancer in Piedmont and Liguria. Methods and study design. Sixteen centers (11 from Piedmont and 5 from Liguria) received and answered by email a questionnaire data base about clinical and technical aspects of the treatment of rectal cancer. All data were incorporated in a single data base and analyzed. Results. Data regarding 593 patients who received radiotherapy for rectal cancer during the year 2009 were collected and analyzed. Staging consisted in colonoscopy, thoracic and abdominal CT, pelvic MRI and endoscopic ultrasound. PET/CT was employed to complete staging and in the treatment planning in 12/16 centers (75{\%}). Neoadjuvant radiotherapy was employed more frequently than adjuvant radiotherapy (50{\%} vs 36.4{\%}), using typically a total dose of 45 Gy with 1.8 Gy/fraction. Concurrent chemoradiation with 5-fluorouracil or capecitabine was mainly employed in neoadjuvant and adjuvant settings, whereas oxaliplatin alone or in combination with 5-FU or capecitabine and leucovorin was commonly employed as the adjuvant agent. The median interval from neoadjuvant treatment to surgery was 7 weeks after longcourse radiotherapy and 8 days after short-course radiotherapy. The pelvic total dose of 45 Gy in the adjuvant setting was the same in all the centers. Doses higher than 45 Gy were employed with a radical intent or in case of positive surgical margins. Hypofractionated regimens (2.5, 3 Gy to a total dose of 35-30 Gy) were used in the palliative setting. No relevant differences were observed in target volume definition and patient setup. Twenty-six patients (4.4{\%}) developed grade 3 acute toxicity. Follow-up was scheduled in a similar way in all the centers. Conclusions. No relevant differences were found among the centers involved in the survey. The approach can help clinicians to address important clinical questions and to improve consistency and homogeneity of treatments.",
keywords = "Management, Rectal cancer, Survey",
author = "{Di Genesio Pagliuca}, Milena and Lucia Turri and Fernando Munoz and Antonella Melano and Almalina Bacigalupo and Paola Franzone and Piera Sciacero and Vassiliki Tseroni and Vitali, {Maria Laura} and Elena Delmastro and Tindaro Scolaro and Corrado Marziano and Marco Orsatti and Maria Tessa and Annalisa Rossi and Andrea Ballar{\`e} and Gregorio Moro and Rachele Grasso and Marco Krengli",
year = "2013",
month = "1",
doi = "10.1700/1248.13790",
language = "English",
volume = "99",
pages = "61--67",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Patterns of practice in the radiation therapy management of rectal cancer

T2 - Survey of the Interregional Group Piedmont, Valle d'Aosta and Liguria of the "associazione Italiana di Radioterapia Oncologica (AIRO)"

AU - Di Genesio Pagliuca, Milena

AU - Turri, Lucia

AU - Munoz, Fernando

AU - Melano, Antonella

AU - Bacigalupo, Almalina

AU - Franzone, Paola

AU - Sciacero, Piera

AU - Tseroni, Vassiliki

AU - Vitali, Maria Laura

AU - Delmastro, Elena

AU - Scolaro, Tindaro

AU - Marziano, Corrado

AU - Orsatti, Marco

AU - Tessa, Maria

AU - Rossi, Annalisa

AU - Ballarè, Andrea

AU - Moro, Gregorio

AU - Grasso, Rachele

AU - Krengli, Marco

PY - 2013/1

Y1 - 2013/1

N2 - Aims and background. To report the survey about the main aspects on the use of radiotherapy for the treatment of rectal cancer in Piedmont and Liguria. Methods and study design. Sixteen centers (11 from Piedmont and 5 from Liguria) received and answered by email a questionnaire data base about clinical and technical aspects of the treatment of rectal cancer. All data were incorporated in a single data base and analyzed. Results. Data regarding 593 patients who received radiotherapy for rectal cancer during the year 2009 were collected and analyzed. Staging consisted in colonoscopy, thoracic and abdominal CT, pelvic MRI and endoscopic ultrasound. PET/CT was employed to complete staging and in the treatment planning in 12/16 centers (75%). Neoadjuvant radiotherapy was employed more frequently than adjuvant radiotherapy (50% vs 36.4%), using typically a total dose of 45 Gy with 1.8 Gy/fraction. Concurrent chemoradiation with 5-fluorouracil or capecitabine was mainly employed in neoadjuvant and adjuvant settings, whereas oxaliplatin alone or in combination with 5-FU or capecitabine and leucovorin was commonly employed as the adjuvant agent. The median interval from neoadjuvant treatment to surgery was 7 weeks after longcourse radiotherapy and 8 days after short-course radiotherapy. The pelvic total dose of 45 Gy in the adjuvant setting was the same in all the centers. Doses higher than 45 Gy were employed with a radical intent or in case of positive surgical margins. Hypofractionated regimens (2.5, 3 Gy to a total dose of 35-30 Gy) were used in the palliative setting. No relevant differences were observed in target volume definition and patient setup. Twenty-six patients (4.4%) developed grade 3 acute toxicity. Follow-up was scheduled in a similar way in all the centers. Conclusions. No relevant differences were found among the centers involved in the survey. The approach can help clinicians to address important clinical questions and to improve consistency and homogeneity of treatments.

AB - Aims and background. To report the survey about the main aspects on the use of radiotherapy for the treatment of rectal cancer in Piedmont and Liguria. Methods and study design. Sixteen centers (11 from Piedmont and 5 from Liguria) received and answered by email a questionnaire data base about clinical and technical aspects of the treatment of rectal cancer. All data were incorporated in a single data base and analyzed. Results. Data regarding 593 patients who received radiotherapy for rectal cancer during the year 2009 were collected and analyzed. Staging consisted in colonoscopy, thoracic and abdominal CT, pelvic MRI and endoscopic ultrasound. PET/CT was employed to complete staging and in the treatment planning in 12/16 centers (75%). Neoadjuvant radiotherapy was employed more frequently than adjuvant radiotherapy (50% vs 36.4%), using typically a total dose of 45 Gy with 1.8 Gy/fraction. Concurrent chemoradiation with 5-fluorouracil or capecitabine was mainly employed in neoadjuvant and adjuvant settings, whereas oxaliplatin alone or in combination with 5-FU or capecitabine and leucovorin was commonly employed as the adjuvant agent. The median interval from neoadjuvant treatment to surgery was 7 weeks after longcourse radiotherapy and 8 days after short-course radiotherapy. The pelvic total dose of 45 Gy in the adjuvant setting was the same in all the centers. Doses higher than 45 Gy were employed with a radical intent or in case of positive surgical margins. Hypofractionated regimens (2.5, 3 Gy to a total dose of 35-30 Gy) were used in the palliative setting. No relevant differences were observed in target volume definition and patient setup. Twenty-six patients (4.4%) developed grade 3 acute toxicity. Follow-up was scheduled in a similar way in all the centers. Conclusions. No relevant differences were found among the centers involved in the survey. The approach can help clinicians to address important clinical questions and to improve consistency and homogeneity of treatments.

KW - Management

KW - Rectal cancer

KW - Survey

UR - http://www.scopus.com/inward/record.url?scp=84878139589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878139589&partnerID=8YFLogxK

U2 - 10.1700/1248.13790

DO - 10.1700/1248.13790

M3 - Article

C2 - 23549002

AN - SCOPUS:84878139589

VL - 99

SP - 61

EP - 67

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 1

ER -